Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2009

View Archived Issues

VER-155008 potentiates Hsp90 inhibitor-induced apoptosis in vitro

RO-5068760 exhibits potent preclinical antitumor activity in B-Raf V600E mutant tumors

Schering-Plough describes alpha2C-adrenoceptor agonists for rhinitis

CHMP does not recommend approval of Roche's bevacizumab for GBM

FDA extends PDUFA date for Neuromed's NDA for Exalgo

CHMP formally adopts negative opinion on Antigenics' MAA for Oncophage

FDA accepts as complete response Dendreon's amended BLA for Provenge in CRPC

Pozen initiates enrollment in phase III trials of PA-32540 for heart attack and stroke

Bristol-Myers Squibb reports results from third quarter of 2009

HGS and Aegera Therapeutics initiate HGS-1029 trial in advanced lymphoid tumors

GFT-505 meets all primary endpoints in phase II trial in prediabetic patients

Phase III trial shows ADX-10059 monotherapy to be effective in GERD

GM-CSF-expressing adenoviral vector shows clinical benefit in advanced solid tumors

Raptor completes phase II trial of delayed-release cysteamine in cystinosis

Bosentan inhibits the development of pulmonary vascular lesions in hypoxic mice

Deguelin inhibits tumor growth in human colon cancer xenograft mouse model

Rectal dosing of DIMS-0150 improves clinical and histological remission in UC trial

Biotec Pharmacon reports phase III trial results on SBG for diabetic foot ulcer

FDA grants GeoVax's request for pre-IND meeting on therapeutic AIDS vaccine

Nuclear receptor related 1 ligands in early development at sanofi-aventis

Roche and InterMune modifiy phase IIb trial of ITMN-191 in HCV treatment-naive patients

Lilly presents mGluR5 receptor antagonists as anxiolytics

AIST and Kowa identify H4 receptor antagonists for asthma therapy

KineMed receives grant from Daiichi Sankyo for clinical Welchol trial in diabetes type 2

Coenzyme I shows clinical promise in Alzheimer's disease

FDA issues complete response letter regarding BLA for raxibacumab for inhalation anthrax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...